Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05688423 · ClinicalTrials.gov registry record · NA

Integrated Care and Treatment for Severe Infectious Diseases and Substance Use Disorders Among Hospitalized Patients

A NA study of Substance Use Disorders and Injection Site Infection, sponsored by Columbia University.

Active
Registry status
NA
Development phase
480
Enrollment target
6
Study locations

NCT05688423: Active NA study of Substance Use Disorders and Injection Site Infection, sponsored by Columbia University.

NCT05688423 is a NA study of Substance Use Disorders and Injection Site Infection that is active but no longer recruiting, run by Columbia University. The registered enrollment target is 480 participants, roughly in line with the 495-participant average among 93 other Substance Use Disorders trials with a reported enrollment target. The trial reports 6 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05688423, a NA study of Substance Use Disorders and Injection Site Infection, is active but no longer recruiting, sponsored by Columbia University.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
480 participants
Enrollment target
6
Study locations

Study Summary

The goal of this clinical trial is to test the effectiveness of an integrated infectious disease/substance use disorder (SUD) clinical team intervention approach in patients hospitalized with severe injection-related infections (SIRI) who use drugs. The main question this study aims to answer is whether this intervention approach will be associated with lower mortality and fewer hospital readmissions. Participants will participate in the integrated SUD/ID care team intervention (SIRI Team). Researchers will compare this intervention to treatment as usual (TUA) to see if there are any differences in health outcomes.

Primary Outcome

Binary: A participant is alive with no hospital readmission 4 months post-randomization vs. a participant has died or been readmitted to the hospital within 4 months post-randomization

Interventions

  • BEHAVIORAL Treatment as Usual
  • BEHAVIORAL SIRI Team

Study Locations (6)

Florida

  • University of Miami - Jackson Memorial Hospital - Miami
  • Tampa General Hospital - Tampa

Alabama

  • University of Alabama at Birmingham - Birmingham

New Mexico

  • University of New Mexico Health Sciences Center - Albuquerque

Pennsylvania

  • University of Pennsylvania - Philadelphia

Utah

  • University of Utah Hospital - Salt Lake City

Trial Details

FieldValue
Enrollment Target 480 participants
Start Date 2024-01-05
Est. Completion 2027-04-03
Phase NA
Columbia University

958 total trials

What the registry record for NCT05688423 still lists

NCT05688423 is an interventional study that assigns participants to a tested intervention. The registered 480 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 495-participant average among 93 other Substance Use Disorders trials with a reported enrollment target.

The record links to 2 conditions, with Substance Use Disorders appearing as the primary indexed condition, and to 2 interventions - of which Treatment as Usual is the first listed.

NCT05688423 lists 6 locations in 5 states (Florida, Alabama, New Mexico).

Frequently Asked Questions

What is clinical trial NCT05688423 about?

NCT05688423 is a clinical study titled "Integrated Care and Treatment for Severe Infectious Diseases and Substance Use Disorders Among Hospitalized Patients". The goal of this clinical trial is to test the effectiveness of an integrated infectious disease/substance use disorder (SUD) clinical team intervention approach in patients hospitalized with severe injection-related infections (SIRI) who use drugs. The main question this study aims to answer is whe...

What is the current status of trial NCT05688423?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 480 participants. The study started on 2024-01-05. Estimated completion is 2027-04-03.

What conditions does trial NCT05688423 study?

This clinical trial studies the following conditions: Substance Use Disorders, Injection Site Infection.

What interventions are being tested in trial NCT05688423?

The interventions under investigation include: Treatment as Usual (BEHAVIORAL), SIRI Team (BEHAVIORAL).

Who is sponsoring clinical trial NCT05688423?

This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05688423 being conducted?

This trial has 6 study locations across Alabama, Florida, New Mexico, Pennsylvania, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Substance Use Disorders

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05688423's enrollment target sits among peer trials

480 7th of 93 higher than 87 of 93 other Substance Use Disorders trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Substance Use Disorders trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01954992 · 480 participants · Phase 3

    Glufosfamide Versus 5-FU in Second Line Metastatic Pancreatic Cancer

  • NCT03023696 · 480 participants · NA

    Can Prophylactic Foraminotomy Prevent C5 Palsy

  • NCT04948060 · 480 participants · NA

    Tribally Engaged Approaches to Lung Screening (TEALS)

  • NCT05053230 · 480 participants · NA

    A Study Evaluating the Integrative Medicine at Home (IM@HOME) Program in People With Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05688423, the US trial registry maintained by the National Library of Medicine. NCT05688423 (mid enrollment · multi site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.